During development, haemogenesis occurs invariably at sites of vasculogenesis. Between embryonic day (E) 9.5 and E10.5 in mice, endothelial cells in the caudal part of the dorsal aorta generate haematopoietic stem cells 1, 2 and are referred to as haemogenic endothelium [3] [4] [5] [6] [7] [8] . The mechanisms by which haematopoiesis is restricted to this domain, and how the morphological transformation from endothelial to haematopoietic is controlled are unknown. We show here that HoxA3, a gene uniquely expressed in the embryonic but not yolk sac vasculature, restrains haematopoietic differentiation of the earliest endothelial progenitors, and induces reversion of the earliest haematopoietic progenitors into CD41negative endothelial cells. This reversible modulation of endothelial-haematopoietic state is accomplished by targeting key haematopoietic transcription factors for downregulation, including Runx1, Gata1, Gfi1B, Ikaros, and PU.1. Through loss-of-function, and gain-of-function epistasis experiments, and the identification of antipodally regulated targets, we show that among these factors, Runx1 is uniquely able to erase the endothelial program set up by HoxA3. These results suggest both why a frank endothelium does not precede haematopoiesis in the yolk sac, and why haematopoietic stem cell generation requires Runx1 expression only in endothelial cells.
Homeobox genes have an important role during vertebrate development, determining cell identity along the rostral-caudal axis. In early development, they are expressed along this axis in a manner co-linear with their order in the Hox cluster 9 . In some tissues, these rostral-caudal expression patterns are reset during organogenesis; for example, several Hox genes have been identified in haematopoietic stem cells (HSCs), and their expression patterns change during differentiation [10] [11] [12] [13] . Expression of Hox paralogue group 4 members, including HoxB4, promotes self-renewal of HSCs [14] [15] [16] and allows engraftment of early embryonic haematopoietic progenitors produced in vitro from embryonic stem cells 17 . Hox paralogue group 3, the next anterior, is best known for specifying the identity of tissues that originate from the pharyngeal arches. However it also has an important role in endothelial development. Mice that lack HoxA3 have cardiovascular abnormalities 18 ; vascular expression of paralogue group 3 members is associated with angiogenesis and wound repair [19] [20] [21] . Growing evidence suggests that the embryonic vasculature gives rise to haematopoietic progenitors through a specialized haemogenic endothelium 3, 22, 23 . The posterior dorsal aorta is one such specialized site that has a particularly important role in the origin of the adult HSC pool, through a poorly understood process that is dependent on Runx1 (ref. 5) . The vascular role of paralogue group 3 prompted us to evaluate the temporal expression of HoxA3 in the haemogenic domains of the dorsal aorta. In early development (E7.5), HoxA3 expression is restricted to the embryo proper, whereas Runx1 expression marks haematopoiesis in the yolk sac ( Supplementary Information, Fig. 1a, b ). HoxA3 and Runx1 show a remarkable pattern of mutually exclusive expression at haematopoietic and vascular sites in the early embryo. At E8.25 and E8.5, HoxA3 is highly expressed throughout the neurectoderm and mesenchyme, is present at intermediate levels in the endothelium of both the anterior and posterior dorsal aortae, and remains absent from the yolk sac ( Fig. 1a , c; Supplementary Information, Fig. S1c, e ). By contrast, Runx1 is found in the yolk sac but not in the aortae or other embryonic vessels ( Fig. 1b , d Supplementary Information, Fig. S1d , f), except for the omphalomesenteric artery, as seen previously 24, 25 . Notably, HoxA3 is not expressed in the omphalomesenteric artery ( Fig. 1c ). At E9.5 and E10.5, the time point at which the posterior dorsal aorta first begins to express Runx1 and become haemogenic, HoxA3 expression in the aortic endothelial cells is clearly lost ( Fig. 1e , g; Supplementary Information, Fig. S1g , i), but Runx1 is expressed ( Fig. 1f , h; Supplementary Information, Fig. 1h , j).
HoxA3 downregulation thus marks the site of haemogenesis in the endothelium of the dorsal aorta. Does HoxA3 expression have any functional effect on the development of haemogenic endothelium? To answer this question, we generated a doxycycline-inducible HoxA3 murine embryonic stem cell line by cassette exchange recombination into a doxinducible locus 16 , and differentiated these cells as embryoid bodies. The kinetics of mesoderm differentiation in this system broadly mimics that of embryonic development 26 , with bipotent haematopoietic-endothelial progenitors (haemangioblasts), identified in clonal assays as early as 2.75 days of differentiation 27 , and corresponding to embryonic bipotent progenitors of the posterior primitive streak, thought to contribute to yolk sac haematopoiesis 28 . Vascular markers, such as VE-cadherin, Tie2 and CD31, first appear two days later, co-expressed on many cells with the earliest haematopoietic marker, CD41 (ref. 29, 30) . The co-expressing population is capable of both endothelial and haematopoietic differentiation, thus defining it as haemogenic endothelium 31, 32 . When we induced HoxA3 with doxycycline just before this time (day 4-6), we noted a striking repression of the haematopoietic markers CD41 + and CD45 + (Fig. 2a, b ). However, the total endothelial progenitor population identified as cells expressing both Flk1 and VE-cadherin 33, 34 (F/V population) was not reduced by HoxA3 expression ( Fig. 2a, b ). We assayed haematopoietic progenitor content in these embryoid bodies and found that HoxA3 markedly suppressed haematopoietic colony-forming cell (CFC) content, (Fig. 2c ), demonstrating that HoxA3 was not merely preventing expression of surface markers, but truly preventing haematopoietic differentiation. When haematopoietic progenitors (c-Kit CD41 double-positive cells) from uninduced embryoid bodies were sorted and plated in CFC assays, HoxA3 expression in the methylcellulose medium abolished haematopoietic colony-forming potential (Supplementary Information, Fig. 2a ). To determine whether the haematopoietic repression of HoxA3 was caused by cell death or a change in cell fate, haematopoietic (c-Kit + / CD41 + ; K/41), and endothelial (Flk1 + /VE-cadherin + ; F/V) fractions were purified from day 6 embryoid bodies and cultured on OP9 stromal cells, a system that supports both haematopoiesis and endothelial development. In the absence of doxycycline, both the F/V and K/41 fractions produced haematopoietic cells, consistent with the notion that the endothelial fraction is endowed with haemogenic capacity 32 (Fig. 2f , g, no dox). However when HoxA3 was upregulated, expression of haematopoietic markers was significantly reduced ( Fig. 2f , g, +dox). Remarkably, in the presence of doxycycline, not only were haematopoietic cells missing from the K/41 fraction, but colonies of cells with an epithelial morphology and expressing VE-cadherin were observed instead ( Fig. 2e ). The induction of endothelial markers and repression of haematopoietic markers was also seen in more committed progenitors already expressing the panhaematopoietic marker CD45 ( Supplementary Information, Fig. S2b ). When HoxA3 expression was withdrawn, haematopoietic colonies developed again, in both K/41 and F/V-initiated cultures ( Fig. 2d-g ). This result shows that HoxA3 reversibly restrains haematopoietic development and maintains an endothelium, even in progenitors that have been recently committed to haematopoiesis, as indicated by expression of CD41 and CD45.
To test the effect of HoxA3 in bona fide haemogenic endothelium 6-8 , we expressed HoxA3 with an ires-GFP reporter by retroviral transduction in disaggregated E10.5 aorta-gonad-mesonephros (AGM) tissue cultured ex vivo. Both GFP+ haematopoietic and GFP+ adherent colonies could be detected in cultures transduced with control vector. However with the HoxA3 vector, only GFP-negative haematopoietic colonies were found, whereas GFP+ colonies were adherent (Supplementary Information, Fig. S3a ). Flow cytometry analysis confirmed that cells expressing HoxA3 had elevated Flk-1 and VE-cadherin expression, and reduced CD41 and CD45 expression ( Supplementary Information, Fig. S3b ). Thus HoxA3 can repress haematopoietic development in both embryonic stem cell-derived haematopoieitic progenitors and in embryonic AGM-derived tissue.
To gain insight into the mechanism by which HoxA3 regulates the haemogenic transition, we performed transcriptional profiling on both the endothelial and haematopoietic progenitor fractions from day 6 embryoid bodies treated with doxycycline for 6 h (Fig. 3 ). In the haematopoietic (K/41) fraction, HoxA3 regulated 585 genes, of which 277 were repressed and 308 were upregulated ( Fig. 3a , P <0.05 ). Because HoxA3 promotes the endothelial phenotype in this fraction and inhibits haematopoiesis, we evaluated genes upregulated by HoxA3 on the basis of their expression in control haematopoietic or endothelial fractions. Genes involved in endothelial development clustered together, were expressed at higher levels in the control F/V fraction, compared with the control K/41 fraction, and were generally upregulated by HoxA3 in the doxycycline-treated K/41 fraction (Fig. 3b ). We performed a similar analysis for the F/V fraction in which 832 genes were regulated ( Fig. 3a , 421 down and 411 up; P <0.05). Genes repressed by HoxA3 included many known haematopoietic regulators, most of which are expressed HoxA3 Runx1
Reciprocal expression of HoxA3 and Runx1 in embryonic endothelium. (a-h) In situ hybridization of E8.25-E10.5 embryonic tissues with HoxA3 (a, c, e, g) and Runx1 (b, d, f, h) probes.) HoxA3, but not Runx1, is expressed in aortic endothelial cells. Note that Runx1, but not HoxA3 is expressed in the yolk sac (black arrowheads) (a, b). At E8.5, HoxA3 expression begins to decline in aortic endothelium, but Runx1 is still not detected. Note that the omphalomesenteric artery is negative for HoxA3, but positive for Runx1 (c, d). The boxed areas in the left panels are magnified in the right panels (a-d). In situ hybridization of dissected E9.5 and E10.5 AGMs (e-h, left panels). At E9.5, HoxA3 expression is barely detectable in aortic endothelial cells, whereas Runx1 expression is now observed (e, f). At E10.5, HoxA3 expression is completely abolished in aortic endothelial cells, whereas Runx1 expression has increased (g, h). A, aorta; G, gut tube; NT, neural tube; OA, omphalomesenteric artery. Stippled lines in e-h outline aorta. Scale bar, 50 μm for lower magnification panels and AGM explants, and 10 μm for higher magnification panels.
at higher levels in control K/41 cells, compared with control F/V cells ( Fig. 3c ). In this cluster, HoxA3 significantly repressed the expression of Runx1, Gata1, Gfi1B, Ikaros, PU.1 and Phemx, all validated by qPCR ( Fig. 3d ). HoxA3 thus coordinately regulates a large number of genes involved in endothelial and haematopoietic development, preventing the haematopoietic program from arising in endothelial progenitors and reactivating an endothelial program in nascent haematopoietic progenitors. It is the first regulatory factor identified to date to have this effect. One of the notable downregulated targets is Runx1. Loss-of-function analysis of Runx1 showed that it is essential for definitive haematopoiesis 35, 36 and for the emergence of haematopoietic cells from the aorta 24 . Conditional deletion of Runx1 has shown that its role is essential in VE-cadherin-positive cells of the aorta, but dispensable in the (Vav1expressing) haematopoietic stem cells themselves 5 . To determine the functional relevance of Runx1 and other haematopoietic transcription factors repressed by HoxA3, we performed dominant epistasis experiments. Endothelial (F/V) progenitor cells from HoxA3-induced embryoid bodies were sorted and transduced with Runx1B, Ikaros, Pu.1, Gata1, Gfi1B, or control vectors bearing ires-GFP reporters, and cultured on OP9 stroma. HoxA3 expression was maintained with doxycycline. Surface marker analysis of GFP-gated cells demonstrated that Runx1 markedly suppressed, Gata1 partially suppressed, and Gfi1B minimally suppressed the HoxA3 phenotype, whereas Pu.1 and Ikaros had no effect (Fig. 4a, b) . Transcriptional analysis showed that Gfi1B, PU.1, Ikaros, and Phemx, were actually target genes of Runx1, but that GATA1 was not (Fig. 4c ). To understand this epistasis, we sorted Runx1-or Gata1-transduced, HoxA3-expressing cells, and determined their global gene expression profiles in comparison with HoxA3-expressing cells (with control GFP vector), or cells in which HoxA3 expression was turned off by doxycycline withdrawal. Consistent with their ability to induce reversion of the HoxA3 phenotype, high level overexpression of both Runx1 and Gata1 caused reversion of many of the gene expression changes induced by HoxA3, particularly those genes that were repressed by HoxA3, including Gfi1B and other haematopoietic transcription factors (Fig. 4d ). However, Runx1 was far more potent than Gata1 in repressing genes that were upregulated by HoxA3, including many key endothelial regulatory factors, as well as regulators of adhesion and polarity (Fig. 4e) .
We tested putative HoxA3 recognition sequences within the Runx1 locus by ChIP and found that several, including a conserved sequence upstream of the P2 enhancer, were sites of direct binding (Supplementary Information Fig. S4a, b) . We then tested whether the loss of HoxA3 would lead to derepression of Runx1 in vivo by performing in situ hybridization with Runx1 probe on HoxA3 mutant embryos 37 . At E8.25, Runx1 expression was never detected in the dorsal aortae of wild-type (0/24) or heterozygous (0/41) embryos, but was found in a significant number of null embryos (14/29). We observed precocious expression of Runx1 in endothelial cells of the dorsal aortae, and occasionally in excess haematopoietic cells within the aortic lumen ( Fig. 5a ), demonstrating that HoxA3 represses Runx1 in vivo.
These data demonstrate that HoxA3 sits at the apex of a cascade of regulatory factors, such that the spatiotemporal regulation of HoxA3 expression determines where and when haemogenic potential arises within embryonic vessels. HoxA3 represses haemogenesis in part by blocking the expression of Runx1, which would otherwise erase the endothelial program and activate numerous downstream transcription factors to promote haematopoietic development. This finding has implications for the two modes of haematopoiesis in early embryonic development: yolk sac mesoderm, which does not express HoxA3, undergoes synchronous haematopoietic and endothelial differentiation, whereas haematopoietic differentiation from lateral plate mesoderm, which expresses HoxA3, is delayed, and occurs by budding from a well-defined endothelium. It is notable that Runx1 was shown to be required only transiently, and in the endothelial cells, not the derived haematopoietic cells, of the AGM 5 .
The expression profile of cells expressing both HoxA3 and Runx1 indicates that an essential role of Runx1 is to extinguish an endothelial program. This is a transient requirement, and not necessary in the yolk sac where endothelial and haematopoietic cells develop concurrently, not sequentially, but required in the AGM where haematopoietic cells emerge from an endothelium. Our model is summarized in Fig. 5b : endothelial progenitors produced in lateral plate mesoderm are inhibited from further differentiation towards haematopoeisis by HoxA3, which represses Runx1 and other key haematopoietic transcription factors. HoxA3 is then extinguished in a subset of endothelium, allowing haemogenesis to occur. Although the presence of a haemogenic endothelium has been appreciated for almost a century 38 , the spatiotemporal patterning of the embryonic endothelium into haemogenic and non-haemogenic domains, and the regulation of the endothelial-haematopoietic transition have remained inscrutable. The data presented here demonstrates that HoxA3 has a crucial role in both processes by acting as a gatekeeper at the apex of the transcriptional hierarchy restricting entry into the haematopoietic program.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Note: Supplementary Information is available on the Nature Cell Biology website.
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Methylcellulose colony assays.
For each colony assay, 50,000 cells were plated into 1.5 ml methylcellulose medium supplemented with IL3, IL6, Epo, and SCF (M3434, StemCell Technologies), and where indicated, doxycycline (1 μg ml -1 ). Primitive erythroid colonies were counted after 6 days, other colonies after 10 days.
OP9 co-cultures. 200,000 c-Kit + /CD41 + or Flk-1+/VE-cad+ cells from day 6 embryoid bodies were purified by flow cytometry and plated on OP9 monolayers (50,000 OP9 cells per well preplated in 6-well dishes one day prior) in IMDM supplemented with 10% FBS, 5 ng ml -1 VEGF, 40 ng ml -1 TPO, 40 ng ml -1 Flt-3 ligand, penicillin/streptomycin (from ×100, Gibco), 2 mM glutamax, and 0.5 ug ml -1 doxycycline at 37°C in 5% CO 2 , 5% O 2 . Semi-adherant cells were passaged by trypsinization every 4-5 days and replated at a density of 50,000 cells per well in 6-well dishes.
For ex vivo AGM cultures, 6 AGMs were pooled and dissociated with 0.25% collagenase I. Cells were then transduced either with control (pMSCV-iresGFP) or HoxA3 retroviral vector (pMSCV-HoxA3-iresGFP) and co-cultured on OP9 monolayers in IMDM supplemented with 10% FBS, 5 ng ml -1 VEGF, 40 ng ml -1 TPO, 40 ng ml -1 Flt-3 ligand, 5 ng ml -1 IL3, 50 ng ml -1 Ang1, 1000 U ml -1 LIF (Millipore), penicillin/streptomycin (Gibco), 2 mM glutamax, at 37°C in 5% CO 2 , 5% O 2 . Retroviral transduction of pMSCV-ires-GFP, MSCV-Runx1B, (gift from S. Tsuzuki; Aichi Cancer Center Research Institute, Japan) PU.1-(BC003815), Ikaros-(BC018349), Gfi1B-(BC052654) Gata1-(NM_008089.1) ires-GFP were performed on day 6 FV sorted progenitors. Retroviral transduction of pMSCV-ires-GFP, MSCV-Runx1B, (gifts from S. Tsuzuki), MSCV-PU.1, MSCV-Ikaros, MSCV-Gata1 and MSCV-Gfi1B were performed as reported previously 17 .
Embryo in situ hybridization. HoxA3 (Y11717) and Runx1 (BC069929) were used as templates for digoxigenin-labelled probes. Hybridizations were performed as described previously 40 . The HoxA3 knockout mice were provided by Mario Capecchi (University of Utah, USA).
Chromatin immunoprecipitation (ChIP).ChIP was performed by using Magna ChIP G protocol (Millipore). Embryoid bodies were cultured as described above, and induced from day 4-6. Between 10 7 and 2×10 7 disaggregated day 6 embryoid body cells were crosslinked for 5 min with 1% formaldehyde, and lysed. Chromatin was sheared to obtain DNA fragments between 200 and 500 bp. Immunoprecipitations used goat anti-mouse HoxA3 polyclonal (HoxA3G-14 SC22384, Santa Cruz) and IgG control (Chrompure goat IgG) antibodies (10 μg antibody in 100 μl). The following primer sets were used for qPCR: N1:F, 5ʹ-ttggaactcttagccttgggacc-3ʹ; R, 5ʹ-tagatgcttcccagagaagtg-3ʹ; N2: F, 5ʹ-tactctgggtagtccagtatttgg-3ʹ; R, 5ʹ-cctatgacaaaggactaatcagagtg-3ʹ; H1: F, 5ʹ-cctctcatttcacgttgcag-3ʹ; R, 5ʹ-ggcttcacatttggaccagt-3ʹ; H2: F, 5ʹ-ttccgtaatcctggcatgcag-3ʹ; R, 5ʹ-agtctttgctgtgcagtttc-3ʹ; H4: F, 5ʹagcagcagaagactgcagg-3ʹ; R 5ʹ-agtgcagatcactcgagg-3ʹ; H5: F, 5ʹ-cctgaggatcaagctcgtgt-3ʹ; R, 5ʹ-tgggtgaaaaggaggtcatc-3ʹ Microarray experiments. HoxA3 was induced with doxycycline (1 μg ml -1 ) in day 5 + 18 h embryoid bodies, and cells were collected 6 h later, at day 6. Three independent experiments were performed. cRNA was hybridized to MouseWG-6 Bead Chip Arrays (Illumina). Raw data were processed using Beadstudio (Illumina) and analysed on Genespring GX 7.3.1 (Agilent). For microarray experiments of inducible HoxA3 FV cells transduced with Gata1 or Runx1, cells were cultured on OP9, 5000 GFP+ cells were sorted, RNA was amplified by using SuperAmp (Miltenyi) amplification and Cy3-labelled cDNAs hybridized to Agilent Whole Mouse Genome Oligo Microarray 4 X 44K. Microarray data have been deposited in the NCBI Gene Expression Omnibus, GSE25096 (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE25096).
For qPCR validation, probes for HoxA3, Runx1, Gata1, PU.1, Ilk, Lycat, Nr2f2 and PlexinB1 were purchased from Applied Biosystems. Additional qPCR primers were: Gfi1b, 5ʹ-CTAGAAAGGACCGTGGCATT-3ʹ 5ʹ-CAGGG-ACA GTGTGGAGGTTC-3ʹ; Phemx, 5ʹ-AGAATCTCCAGAAGGC CACC-3ʹ 5ʹ-GAGCACCAT AGCCACTGTGA-3ʹ; Ikaros (Ikzf1), 5ʹ-GCC TTTCT GGGT-AAAGGAGG-3ʹ 5ʹ-TGTCCACTACCTCTGGAGCA-3ʹ. 
